Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure

Clin Genitourin Cancer. 2016 Aug;14(4):261-264.e4. doi: 10.1016/j.clgc.2016.03.020. Epub 2016 Mar 24.

Authors

Andrea Necchi¹, Andrea Anichini², Daniele Raggi², Patrizia Giannatempo², Domenico Magazzù³, Nicola Nicolai², Maurizio Colecchia², Biagio Paolini², Elisa Coradeschi³, Elena Tassi², Giulia Grazia², Roberta Mortarini², Giuseppina Calareso², Raffaella De Fato³, Elena Togliardi², Flavio Crippa², Roberto Salvioni², Pinuccia Valagussa³, Alessandro M Gianni²

Affiliations

¹ Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: andrea.necchi@istitutotumori.mi.it.
² Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
³ Fondazione Michelangelo, Milano, Italy.

PMID: 27105722
DOI: 10.1016/j.clgc.2016.03.020

No abstract available

Keywords: Brentuximab vedotin; CD30; Embryonal carcinoma; Salvage therapy; Testicular cancer.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / therapeutic use*
Brentuximab Vedotin
Humans
Immunoconjugates / therapeutic use*
Ki-1 Antigen / metabolism*
Neoplasms, Germ Cell and Embryonal / drug therapy*
Neoplasms, Germ Cell and Embryonal / metabolism
Treatment Failure

Substances

Antineoplastic Agents
Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin